Tukysa (tucatinib) is indicated, in combination with trastuzumab and capecitabine, for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Here's a breakdown of the indication:
- What it treats: HER2-positive breast cancer that is advanced (meaning it has spread beyond the breast), unresectable (cannot be surgically removed), or metastatic (has spread to other parts of the body).
- Who it's for: Adult patients who have already received at least one prior anti-HER2-based treatment for metastatic breast cancer. This means Tukysa is generally used as a second-line or later treatment option.
- How it's used: Tukysa is not used alone. It's always given in combination with two other drugs:
- Trastuzumab: Another HER2-targeted therapy, often known by the brand name Herceptin.
- Capecitabine: A chemotherapy drug that is taken orally.
- Important consideration: The indication specifically includes patients with brain metastases, which is a significant feature as many HER2-targeted therapies have limited ability to cross the blood-brain barrier. Tukysa has demonstrated activity in patients with brain metastases.
In summary, Tukysa, alongside trastuzumab and capecitabine, provides a treatment option for advanced HER2-positive breast cancer patients who have previously been treated with other HER2-targeted therapies in the metastatic setting, including those with brain metastases.
